-
Views
-
Cite
Cite
Hans-Georg Wirsching, Isabel Tritschler, Antonella Palla, Christoph Renner, Michael Weller, Ghazaleh Tabatabai, The management of lomustine overdose in malignant glioma patients, Neuro-Oncology Practice, Volume 1, Issue 4, December 2014, Pages 178–183, https://doi.org/10.1093/nop/npu023
- Share Icon Share
Abstract
Lomustine is an oral alkylating drug commonly used for brain tumor patients. Recently, the lomustine-containing PCV polychemotherapy regime (procarbazine, CCNU/lomustine, and vincristine) in combination with radiotherapy has become the standard of care for anaplastic oligodendroglioma with 1p/19q codeletion and high-risk low-grade glioma. Here, we review the literature of all reported cases of lomustine overdose, highlight complications by exemplifying a case of inadvertent lomustine overdose, and outline the management of this potential complication of outpatient PCV therapy.